Macrophage activation syndrome: Why and what should a gastroenterologist know

Journal of Clinical Gastroenterology

Volumn 45, Issue 3, 2011, Pages 210-214

  Jayakar, Bijal A ^a   Hashkes, Philip J ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

infection; inflammatory bowel disease; macrophage activation syndrome; post liver transplantation; rheumatic diseases; sulfasalazine; tumor necrosis factor inhibitors

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; ETOPOSIDE; GAMMA INTERFERON; GLUCOCORTICOID; GOLD DERIVATIVE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIVER ENZYME; MERCAPTOPURINE; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; STEROID; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT ONSET STILL DISEASE; CAUSE OF DEATH; CLINICAL FEATURE; COMA; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; HEMOPHAGOCYTIC SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY TRANSPLANTATION; LABORATORY TEST; LIVER TRANSPLANTATION; MACROPHAGE ACTIVATION SYNDROME; MENTAL HEALTH; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEIZURE; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DISSEMINATED INTRAVASCULAR COAGULATION; HISTOPLASMOSIS; HUMANS; LIVER DISEASES; MACROPHAGE ACTIVATION SYNDROME; MIDDLE AGED; STILL'S DISEASE, ADULT-ONSET; YOUNG ADULT;

EID: 79951812709     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181f6015f     Document Type: Review

References (56)

1. Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr. 1985;106:561-566. (Pubitemid 15080542)
2. Risdall R, Hoppe RT, Warnke R. Non-Hodgkin's lymphoma: a study of the evolution of the disease based upon 92 autopsied cases. Cancer. 1979;44:529-542. (Pubitemid 10220137)
3. Baruchel A, Schaison G. Syndromes of inappropriate macrophage activation in childhood. Nouv Rev Fr Hematol. 1990; 32:415-420.
4. Stephan JL, Zeller J, Hubert P, et al. Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol. 1993;11:451-456. (Pubitemid 23287170)
5. Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390-392. (Pubitemid 38160763)
6. Reiner AP, Spivak JL. Hematophagic histiocytosis. A report of 23 new patients and a review of the literature. Medicine (Baltimore). 1988;67:369-388. (Pubitemid 19003323)
7. Grom AA. Natural killer cell dysfunction: A common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis? Arthritis Rheum. 2004;50:689-698. (Pubitemid 38326166)
8. Grom AA. Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities? Curr Opin Rheumatol. 2003;15:587-590. (Pubitemid 37041397)
9. Wulffraat NM, Rijkers GT, Elst E, et al. Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxford). 2003;42:375-379. (Pubitemid 36312936)
10. Grom AA, Villanueva J, Lee S, et al. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr. 2003;142:292-296. (Pubitemid 36338013)
11. Arico M, Danesino C, Pende D, et al. Pathogenesis of haemophagocytic lymphohistiocytosis. Br J Haematol. 2001; 114:761-769. (Pubitemid 32953731)
12. Davies SV, Dean JD, Wardrop CA, et al. Epstein-Barr virus-associated haemophagocytic syndrome in a patient with juvenile chronic arthritis. Br J Rheumatol. 1994;33: 495-497. (Pubitemid 24153978)
13. Hoang MP, Dawson DB, Rogers ZR, et al. Polymerase chain reaction amplification of archival material for Epstein-Barr virus, cytomegalovirus, human herpesvirus 6, and parvovirus B19 in children with bone marrow hemophagocytosis. Hum Pathol. 1998;29:1074-1077. (Pubitemid 28467526)
14. Rouphael NG, Talati NJ, Vaughan C, et al. Infections associated with haemophagocytic syndrome. Lancet Infect Dis. 2007;7:814-822. (Pubitemid 350152044)
15. Maakaroun NR, Moanna A, Jacob JT, et al. Viral infections associated with haemophagocytic syndrome. Rev Med Virol. 2010;20:93-105.
16. Mehta BM, Hashkes PJ, Avery R, et al. A 21-year-old man with Still's disease with fever, rash, and pancytopenia. Arthritis Care Res (Hoboken). 2010;62:575-579.
17. Singh S, Samant R, Joshi VR. Adult onset Still's disease: a study of 14 cases. Clin Rheumatol. 2008;27:35-39. (Pubitemid 350182675)
18. Ansell BM, Hall MA, Loftus JK, et al. A multicentre pilot study of sulphasalazine in juvenile chronic arthritis. Clin Exp Rheumatol. 1991;9:201-203.
19. Hertzberger-ten Cate R, Cats A. Toxicity of sulfasalazine in systemic juvenile chronic arthritis. Clin Exp Rheumatol. 1991; 9:85-88.
20. Eraso R, Gedalia A, Espinoza LR. Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2002;29:1104; author reply 1104-1105.
21. Ravelli A, Caria MC, Buratti S, et al. Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2001;28: 865-867. (Pubitemid 32246959)
22. Stern A, Riley R, Buckley L. Worsening of macrophage activation syndrome in a patient with adult onset Still's disease after initiation of etanercept therapy. J Clin Rheumatol. 2001; 7:252-256. (Pubitemid 32772086)
23. Zeft A, Hollister R, LaFleur B, et al. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol. 2009;15:161-164.
24. Yeap ST, Sheen JM, Kuo HC, et al. Macrophage activation syndrome as initial presentation of systemic lupus erythematosus. Pediatr Neonatol. 2008;49:39-42.
25. Pringe A, Trail L, Ruperto N, et al. Macrophage activation syndrome in juvenile systemic lupus erythematosus: an underrecognized complication? Lupus. 2007;16:587-592. (Pubitemid 47359993)
26. Parodi A, Davi S, Pringe AB, et al. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum. 2009;60:3388-3399.
27. Lou YJ, Jin J, Mai WY. Ankylosing spondylitis presenting with macrophage activation syndrome. Clin Rheumatol. 2007; 26:1929-1930. (Pubitemid 47516978)
28. Matsumoto H, Fujisawa T, Inui A, et al. Macrophage activation syndrome, the first sign of acute lymphoblastic leukemia in children? J Pediatr. 2001;138:953. (Pubitemid 32545613)
29. Jaffe ES, Costa J, Fauci AS, et al. Malignant lymphoma and erythrophagocytosis simulating malignant histiocytosis. Am J Med. 1983;75:741-749. (Pubitemid 13023280)
30. Allen CE, Yu X, Kozinetz CA, et al. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008;50:1227-1235. (Pubitemid 351555548)
31. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001;85:421-426. (Pubitemid 33702300)
32. Stephan JL, Kone-Paut I, Galambrun C, et al. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology (Oxford). 2001;40:1285-1292.
33. Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol. 2002;14:548-552. (Pubitemid 34953793)
34. Colina M, Govoni M, Trotta F. Fatal myocarditis in adultonset Still disease with diffuse intravascular coagulation. Rheumatol Int. 2009;29:1355-1357.
35. Russo RA, Rosenzweig SD, Katsicas MM. Hepatitis Aassociated macrophage activation syndrome in children with systemic juvenile idiopathic arthritis: report of 2 cases. J Rheumatol. 2008;35:166-168.
36. Chauveau E, Terrier F, Casassus-Buihle D, et al. Macrophage activation syndrome after treatment with infliximab for fistulated Crohn's disease. Presse Med. 2005;34:583-584. (Pubitemid 40646511)
37. James DG, Stone CD, Wang HL, et al. Reactive hemophagocytic syndrome complicating the treatment of inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:573-580. (Pubitemid 43977738)
38. Siegel CA, Bensen SP, Ely P. Should rare complications of treatment influence decision-making in ulcerative colitis? Inflamm Bowel Dis. 2007;13:242. (Pubitemid 46806234)
39. de Kerguenec C, Hillaire S, Molinie V, et al. Hepatic manifestations of hemophagocytic syndrome: a study of 30 cases. Am J Gastroenterol. 2001;96:852-857. (Pubitemid 32240744)
40. Billiau AD, Roskams T, Van Damme-Lombaerts R, et al. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gammaproducing lymphocytes and IL-6- and TNF-alpha-producing macrophages. Blood. 2005;105:1648-1651. (Pubitemid 40223686)
41. Davydov VS, Subkhankulova FB, Litvinov RI, et al. Role of Kupffer cells and hepatocytes in fibrinogen catabolism. Vopr Med Khim. 1982;28:83-86. (Pubitemid 12056498)
42. Dharancy S, Crombe V, Copin MC, et al. Fatal hemophagocytic syndrome related to human herpesvirus-6 reinfection following liver transplantation: a case report. Transplant Proc. 2008;40:3791-3793.
43. Karras A, Thervet E, Legendre C. Hemophagocytic syndrome in renal transplant recipients: report of 17 cases and review of literature. Transplantation. 2004;77:238-243. (Pubitemid 38155753)
44. Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. 2005;146:598-604. (Pubitemid 40616243)
45. Bleesing J, Prada A, Siegel DM, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007;56:965-971. (Pubitemid 46399444)
46. Filipovich AH. Hemophagocytic lymphohistiocytosis and other hemophagocytic disorders. Immunol Allergy Clin North Am. 2008;28:293, 313, viii. (Pubitemid 351522416)
47. Schaer DJ, Schleiffenbaum B, Kurrer M, et al. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage- specific marker in the reactive hemophagocytic syndrome. Eur J Haematol. 2005;74:6-10. (Pubitemid 40143680)
48. Mouy R, Stephan JL, Pillet P, et al. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr. 1996;129:750-754. (Pubitemid 27498287)
49. Garcia JE, Lopez AM, de Cabo MR, et al. Cyclosporin A decreases human macrophage interleukin-6 synthesis at posttranscriptional level. Mediators Inflamm. 1999;8:253-259. (Pubitemid 30019336)
50. Makay B, Yilmaz S, Turkyilmaz Z, et al. Etanercept for therapy-resistant macrophage activation syndrome. Pediatr Blood Cancer. 2008;50:419-421.
51. Prahalad S, Bove KE, Dickens D, et al. Etanercept in the treatment of macrophage activation syndrome. J Rheumatol. 2001;28:2120-2124. (Pubitemid 32803794)
52. Ramanan AV, Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2003;30:401-403. (Pubitemid 36152611)
53. Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol. 2008;4:615-620.
54. Tristano AG, Casanova-Escalona L, Torres A, et al. Macrophage activation syndrome in a patient with systemic onset rheumatoid arthritis: rescue with intravenous immunoglobulin therapy. J Clin Rheumatol. 2003;9:253-258. (Pubitemid 36961202)
55. Gupta AA, Tyrrell P, Valani R, et al. Experience with hemophagocytic lymphohistiocytosis/macrophage activation syndrome at a single institution. J Pediatr Hematol Oncol. 2009;31:81-84.
56. Emmenegger U, Frey U, Reimers A, et al. Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes. Am J Hematol. 2001; 68:4-10. (Pubitemid 32738713)